BioLargo Q1 Revenue Plummets 66% to $1.12M, Net Loss Widens Significantly
BLGO is trading near its 52-week low of $0.127 (4.4% above the low).
Summary
BioLargo reported a significant decline in its first-quarter 2026 financial results, with revenue plummeting 66% year-over-year to $1.12 million and net loss nearly doubling to $2.29 million, resulting in a diluted EPS of ($0.01). This substantial revenue drop was primarily attributed to the loss of Pooph private-label pet product sales. While the company highlighted some operational progress, including 90% YoY growth in industrial odor/VOC sales and advancements in its PFAS water treatment and liquid-sodium battery technologies, the overall financial performance is a material negative development. This news contrasts with recent positive announcements regarding strategic partnerships and distribution agreements, indicating that these initiatives have not yet translated into improved financial results. Given the company's ~$42 million market cap and its stock trading near 52-week lows, these results are likely to put further pressure on shares. Traders will closely monitor future reports for signs of revenue recovery and profitability from the new business segments.
At the time of this announcement, BLGO was trading at $0.13 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $42.6M. The 52-week trading range was $0.13 to $0.24. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.